Clinical Trials

Experimental drug cuts dangerous blood sugar episodes by 55% in major Phase 3 trial

Avexitide also delivered significant improvements across all prespecified secondary endpoints

  • By IPP Bureau | November 17, 2026
An experimental drug has delivered promising results in a major Phase 3 clinical trial, reducing dangerous episodes of low blood sugar by 55% in patients suffering from post-bariatric hypoglycemia (PBH), a chronic and potentially debilitating condition that can develop after weight-loss surgery.
 
Amylyx Pharmaceuticals announced that its investigational drug, avexitide, met the primary endpoint of its Phase 3 LUCIDITY trial, demonstrating a highly statistically significant reduction in hypoglycemic events compared with placebo.
 
The 16-week trial results showed that patients receiving avexitide experienced an average of 0.55 hypoglycemic events per week, compared with 1.24 events per week among those receiving placebo. The reduction was statistically significant.
 
The findings could mark a significant breakthrough for people living with PBH, for which there are currently no FDA-approved treatments.
 
Avexitide also delivered significant improvements across all prespecified secondary endpoints. The drug reduced self-monitoring blood glucose-confirmed Level 2 hypoglycemic events by 63%, severe Level 3 events by 47%, and continuous glucose monitoring-detected Level 2 events by 42% compared with placebo.
 
In a secondary analysis, hypoglycemic events fell by 72.9% from baseline among patients receiving avexitide, against a 37.8% reduction in the placebo group.
 
"The presentation of our Phase 3 LUCIDITY results represents a pivotal milestone in our work to address the longstanding treatment gap for people living with PBH. The results shared today reinforce the consistency and strength of the data, with avexitide demonstrating highly statistically significant and clinically meaningful reductions in hypoglycemic events across all prespecified endpoints,” said Camille L. Bedrosian, Chief Medical Officer at Amylyx. 
 
“These positive data, together with positive results from five prior trials of avexitide in PBH, support the potential for avexitide to change practice for this debilitating condition.”
 
Post-bariatric hypoglycemia is a chronic metabolic disorder characterised by recurrent, often unpredictable drops in blood glucose following weight-loss surgery.
 
The condition is believed to be driven by an exaggerated GLP-1 response after eating, triggering excessive insulin secretion and potentially dangerous falls in blood sugar.
 
Symptoms can range from confusion and cognitive impairment to loss of consciousness and seizures. Repeated episodes can compromise patients' safety, independence and quality of life.
 
The disease burden among LUCIDITY participants was substantial. At the start of the trial, 68% reported daily hypoglycemic symptoms, 47% had a history of loss of consciousness, and 28% had previously been hospitalised because of hypoglycemia.
 
“PBH is a chronic metabolic condition characterized by recurrent hypoglycemia. Each hypoglycemic event carries the potential for serious acute consequences and the cumulative burden of living with recurrent and unpredictable events can significantly affect daily functioning, independence, health and quality of life,” said Marilyn Tan, Principal Investigator of the LUCIDITY clinical trial and Clinical Professor at the Stanford School of Medicine. 
 
“The debilitating nature of this condition is clear when you look at the participants of LUCIDITY. At baseline, the majority of participants entered the study experiencing daily hypoglycemia symptoms, with many reporting a history of loss of consciousness and hypoglycemia-related hospitalizations. This substantial disease burden makes the consistent reductions in hypoglycemic events seen with avexitide compelling.”
 
Beyond its efficacy, avexitide was generally well tolerated during the 16-week double-blind treatment period.
 
Most treatment-emergent adverse events were gastrointestinal or related to injection sites and were generally mild to moderate in severity. The trial reported no deaths or treatment-related serious adverse events.
 
Researchers also found no clinically meaningful changes in body weight or fasting plasma glucose during treatment.
 
The LUCIDITY trial enrolled 78 adults who developed PBH following Roux-en-Y gastric bypass surgery. Participants were randomly assigned in a 3:2 ratio to receive either 90mg of avexitide through a daily subcutaneous injection or placebo, alongside standard dietary management.
 
More than 90% completed the double-blind treatment period. All eligible participants subsequently entered the 32-week open-label extension phase.
 
Amylyx is now moving towards a regulatory filing, with the company targeting submission of a New Drug Application (NDA) to the US Food and Drug Administration by the end of 2026. If approved, the company is preparing for a potential commercial launch in 2027.
 
"We're profoundly grateful to everyone who made LUCIDITY possible — from the people living with PBH who participated in our trial, to their families and care partners, as well as the investigators who share our commitment to improve outcomes for this serious condition," said Justin Klee and Joshua Cohen, Co-CEOs of Amylyx. 
 
"These results bring us meaningfully closer to what could be the first approved treatment for a community that has been waiting far too long for one. We're moving with urgency toward an NDA submission by year end and continue to prepare for a potential commercial launch of avexitide in 2027, if approved."

Upcoming E-conference

Other Related stories

Startup

Digitization

Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
(L-R) Manoj Kumar Panicker, General Manager, South Asia, Cytiva and Dr. Sanjib Banerjee, Chief Operating Officer (Biopharma Services), Veeda Lifesciences.